IN SILICO HEAD-TO-HEAD COMPARISON OF INSULIN GLARGINE 300 U/ML AND INSULIN DEGLUDEC IN TYPE 1 DIABETES

被引：0
|
作者：
Visentin, R. [1 ]
Schiavon, M. [1 ]
Giegerich, C. [2 ]
Sieber, J. [2 ]
Man, C. Dalla [1 ]
Cobelli, C. [1 ]
Klabunde, T. [2 ]
机构：
[1] Univ Padua, Dept Informat Engn, Padua, Italy
[2] Sanofi Aventis Deutschland GmbH, Frankfurt, Germany
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
037
引用
收藏
页码：A18 / A18
页数：1
相关论文
共 50 条
  • [31] Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
    Buscemi, Silvio
    Randazzo, Cristiana
    Buscemi, Carola
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (06) : 1595 - 1596
  • [32] New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus
    Goldman, Jennifer
    White, John R., Jr.
    [J]. ANNALS OF PHARMACOTHERAPY, 2015, 49 (10) : 1153 - 1161
  • [33] Glycaemic variability and risk for hypoglycaemia on insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes
    Kovatchev, B.
    Meng, Z.
    Breton, M.
    Leroy, B.
    Cali, A.
    Perfetti, R.
    [J]. DIABETOLOGIA, 2017, 60 : S36 - S37
  • [34] Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL Around Spontaneous Exercise Sessions in Adults with Type 1 Diabetes: A Randomized Cross-Over Trial (ULTRAFLEXI-1 Study)
    Moser, Othmar
    Mueller, Alexander
    Aberer, Felix
    Aziz, Faisal
    Kojzar, Harald
    Sourij, Caren
    Obermayer, Anna
    Abbas, Farah
    Birnbaumer, Philipp
    Lenz, Jacqueline
    Mursic, Ines
    Sternad, Christoph
    Hoenger, Lukas
    Ziko, Haris
    Pferschy, Peter N.
    Tripolt, Norbert
    Sourij, Harald
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 (03) : 161 - 168
  • [35] Variability of insulin degludec and glargine 300 U/mL: A matter of methodology or just marketing?
    Heise, Tim
    Heckermann, Sascha
    DeVries, J. Hans
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (09): : 2051 - 2056
  • [36] Type 2 Diabetes: Direct Comparison between Insulin Glargine and Insulin Degludec
    Lichert, Frank
    [J]. DIABETOLOGIE UND STOFFWECHSEL, 2018, 13 (06) : 546 - 546
  • [37] A comparison of Insulin Glargine U300 and Insulin Degludec around spontaneous exercise sessions in people with type 1 diabetes - the ULTRAFLEXI-1 study
    Moser, Othmar
    Mueller, Alexander
    Aberer, Felix
    Aziz, Faisal
    Kojzar, Harald
    Sourij, Caren
    Obermayer, Anna
    Abbas, Farah
    Birnbaumer, Philipp
    Eckstein, Max
    Hoenger, Lukas
    Lenz, Jaqueline
    Mursic, Ines
    Sternad, Christoph
    Weber, Barbara
    Zanker, Matthias
    Ziko, Haris
    Pferschy, Peter
    Tripolt, Norbert
    Sourij, Harald
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (SUPPL 4) : 251 - 251
  • [38] Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes
    Heise, Tim
    Norskov, Marianne
    Nosek, Leszek
    Kaplan, Kadriye
    Famulla, Susanne
    Haahr, Hanne L.
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (07): : 1032 - 1039
  • [39] Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
    Kovatchev, Boris
    Meng, Zhaoling
    Cali, Anna M. G.
    Perfetti, Riccardo
    Breton, Marc D.
    [J]. DIABETES THERAPY, 2020, 11 (06) : 1293 - 1302
  • [40] Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
    Boris Kovatchev
    Zhaoling Meng
    Anna M. G. Cali
    Riccardo Perfetti
    Marc D. Breton
    [J]. Diabetes Therapy, 2020, 11 : 1293 - 1302
12345